Reference List

1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.New England Journal of Medicine 1999;341(8):556-2.

2. Conry-Cantilena C. Hepatitis C virus diagnostics: technology, clinical applications and impacts. Trends in Biotechnology 1997;15(2):71-6.

3. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997;26(3 Suppl 1):2S-10S.

4. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. Journal of Hepatology 1999;30(5):956-61.

5. Fattovich G, Giustina G, Degos F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. Journal of Hepatology 1997;27(1):201-5.

6. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. Journal of Hepatology 1997;26(1):1-5.Comment in: J Hepatol. 1997 Nov;27(5):953-4.

7. Quan CM, Krajden M, Grigoriew GA, et al. Hepatitis C virus infection in patients infected with the human immunodeficiency virus. Clin Infect Dis 1993;17(1):117-9.

8. Darby SC, Ewart DW, Giangrande PLF, et al. Mortality from liver cancer and liver disease in hemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997;350:1425-31.

9. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349(9055):825-32.

10. Sanchez-Quijano A, Andreu J, Gavilan F, et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. European Journal of Clinical Microbiology and Infectious Diseases 1995;14(11):949-53.

11. Zarski JP, Bohn B, Bastie A, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. Journal of Hepatology 1998;28(1):27-33.

12. Glue P, Rouzier-Panis R, Raffanel C, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 2000;32(3):647-53.

13. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34(2):395-403.

14. Conferences - Management of Hepatitis C 2002.2001; accessed 2002.Web Page. Available at: http://odp.od.nih.gov/consensus/news/upcoming/hepc/hepc_info.htm.

15. Berlin J. Does blinding of readers affect the results of meta-analyses? Lancet 1997;350:185-6.

16. Garbutt JC, West SL, Carey TS, et al. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 1999;281(14):1318-25.

17. Scheim OD, Friedman DS, Fleisher LA, et al. Anesthesia Managment During Cataract Surgery. Evidence Report/Technology Assessment No. 16 (Prepared by the Johns Hopkins University Evidence-based Practice Center under Contract No. 290-097-0006.) AHRQ Publication No. 01-E017.Rockville, MD: Agency for Healthcare Research and Quality; 2001

18. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358(9286):958-65.

19. Saracco G, Ciancio A, Olivero A, et al. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone. Hepatology 2001;34(1):133-8.

20. McHutchison JG, Poynard T, Pianko S, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology 2000;119(5):1317-23.

21. Mangia A, Villani MR, Minerva N, et al. Efficacy of 5 MU of interferon in combination with ribavirin for naive patients with chronic hepatitis C virus: a randomized controlled trial. Journal of Hepatology 2001;34(3):441-6.

22. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. New England Journal of Medicine 2000a;343(23):1666-72.

23. Payen JL, Izopet J, Galindo-Migeot V, et al. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'etude et De Traitement du Virus De L'hepatite C (Get.Vhc). Hepatology 1998;28(6):1680-6.

24. Kumada T, Nakana S, Takeda I, et al. Long-term administration of natural interferon-alpha in patients with chronic hepatitis-C - relationship to serum RNA concentration, HCV-RNA genotypes, histological-changes and hepatitis-C virus. Journal of Gastroenterology and Hepatology 1996;11(2):159-65.

25. Zeuzem S, Teuber G, Naumann U, et al. Randomized, double-blind, placebo-controlled trial of interferon alfa-2a with and without amantadine as initial treatment for chronic hepatitis C. Hepatology 2000;32(4 Pt 1):835-41.

26. Angelico M, Cepparulo M, Barlattani A, et al. Unfavourable effects of colchicine in combination with interferon-alpha in the treatment of chronic hepatitis C. Alimentary Pharmacology and Therapeutics 2000;14(11):1459-67.

27. Shiffman ML, Stewart CA, Hofmann CM, et al. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy. J Infect Dis 2000;182(6):1595-601.

28. Ascione A, De Luca M, Canestrini C, et al. Efficacy of high dose of recombinant alpha 2b interferon on long term response in chronic hepatitis C and cirrhosis: prospective randomized multicentre study. Ital J Gastroenterol and Hepatology 1998;30(5):517-23.

29. Saracco G, Borghesio E, Mesina P, et al. Prolonged treatment (2 years) with different doses (3 versus 6 Mu) of interferon alpha-2b for chronic hepatitis type C: results of a multicenter randomized trial. Journal of Hepatology 1997;27(1):56-62.

30. Craxi A, Di Marco V, Iacono OL, et al. Transfusion-associated chronic hepatitis C: alpha-N-1 interferon for 6 vs. 12 months. Journal of Hepatology 1996;24(5):539-46.

31. Villa E, Grottola A, Buttafoco P, et al. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. American Journal of Gastroenterology 2001;96(10):2973-7.

32. Shiffman ML, Hofmann CM, Gabbay J, et al. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. American Journal of Gastroenterology 2000a;95(10):2928-35.

33. Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, et al. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon. Hepatology 2001;33(3):704-7.

34. Mangia A, Minerva N, Annese M, et al. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C. Hepatology 2001a;33(4):989-93.

35. Villa E, Trande P, Grottola A, et al. Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus: a prospective, double-blind, randomized study. Digestive Diseases and Sciences 1996;41(6):1241-7.

36. Berg T, Hoffmann RM, Teuber G, et al. Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial. Liver 2000;20(6):427-36.

37. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. New England Journal of Medicine 2000;343(23):1673-80.

38. Fortunato G, Castaldo G, Oriani G, et al. Multivariate discriminant function based on six biochemical markers in blood can predict the cirrhotic evolution of chronic hepatitis. Clin Chem 2001;47(9):1696-700.

39. Poynard T, Bedossa P, BioulacSage P, et al. Age and platelet count: A simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. Journal of Viral Hepatitis 1997;4(3):199-208.

40. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069-75.

41. Choi Y, Putti T, Win K, et al. Correlation of viral RNA, alanine aminotransferase, and histopathology in hepatitis C virus-associated hepatitis. Molecular Diagnosis 1999;4(3):251-4.

42. Goldstein NS, Blue DE, Hankin R, et al. Serum alpha-fetoprotein levels in patients with chronic hepatitis C - relationships with serum alanine aminotransferase values, histologic activity index, and hepatocyte MIB-1 scores. Am J Clin Pathol 1999;111(6):811-6.

43. Michielsen PP, Hauben EI, Ramon AM, et al. Serum aminotransferase levels and histological disease in chronic hepatitis C. Acta Gastro-Enterologica Belgica 1997;60(1):11-4.

44. Stanley AJ, Haydon GH, Piris J, et al. Assessment of liver histology in patients with hepatitis-C and normal transaminiase levels. Eur J Clin Gastroenterol Hepatol 1996;8(9):869-72.

45. Assy N, Minuk GY. Serum aspartate but not alanine aminotransferase levels help to predict the histological features of chronic hepatitis C viral infections in adults. American Journal of Gastroenterology 2000;95(6):1545-50.

46. Barbaro G, Di Lorenzo G, Soldini M/Parrotto S, et al. Hepatic glutathione deficiency in chronic hepatitis C: quantitative evaluation in patients who are HIV positive and HIV negative andcorrelations with plasmatic and lymphocytic concentrations and with the activity of liver disease. American Journal of Gastroenterology 1996;91(12):2569-73.

47. Jamal MM, Soni A, Quinn PG, et al. Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States. Hepatology 1999;30(6):1307-11.

48. Luo JC, Hwang SJ, Lai CR, et al. Relationships between serum aminotransferase levels, liver histologies and virological status in patients with chronic hepatitis C in Taiwan. Journal of Gastroenterology and Hepatology 1998;13(7):685-90.

49. McCormick SE, Goodman ZD, Maydonovitch CL, et al. Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C. American Journal of Gastroenterology 1996;91(8):1516-22.

50. Murawaki Y, Ikuta Y, Okamoto K, et al. Diagnostic value of serum markers of connective tissue turnover for predicting histological staging and grading in patients with chronic hepatitis C. Journal of Gastroenterology 2001a;36(6):399-406.

51. Ono E, Shiratori Y, Okudaira T, et al. Platelet count reflects stage of chronic hepatitis C. Hepatology Research 1999;15(3):192-200.

52. Walsh KM, Fletcher A, MacSween RN, et al. Comparison of assays for N-amino terminal propeptide of type III procollagen in chronic hepatitis C by using receiver operating characteristic analysis. European Journal of Gastroenterology and Hepatology 1999;11(8):827-31.

53. Walsh KM, Fletcher A, MacSween RN, et al. Basement membrane peptides as markers of liver disease in chronic hepatitis C. Journal of Hepatology 2000;32(2):325-30.

54. Yeo AET, Ghany M, Conry-Cantilena C, et al. Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. Journal of Viral Hepatitis 2001;8(4):256-63.

55. Anderson FH, Zeng LC, Rock NR, et al. An assessment of the clinical utility of serum ALT and AST in chronic hepatitis C. Hepatol Res 2000;18(1):63-71.

56. Imperiale TF, Said AT, Cummings OW, et al. Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. American Journal of Gastroenterology 2000;95(9):2328-32.

57. Park GJ-H, Lin BPC, Ngu MC, et al. Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis?. Journal of Gastroenterology and Hepatology 2000;15(4):386-90.

58. Sheth SG, Flamm SL, Gordon FD, et al. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. American Journal of Gastroenterology 1998;93(1):44-8.

59. Giannini E, Caglieris S, Ceppa P, et al. Serum pro-collagen III peptide levels are related to lobular necrosis in untreated patients with chronic hepatitis C. Eur J Clin Gastroenterol Hepatol 2001;13(2):137-41.

60. Zylberberg H, Rimaniol AC, Pol S, et al. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. Journal of Hepatology 1999;30(2):185-91.

61. Izzo F, Curley S, Maio P, et al. Correlation of soluble interleukin-2 receptor levels with severity of chronic hepatitis-C virus liver-injury and development of hepatocellular cancer. Surgery 1996;120(1):100-5.

62. Bayati N, Silverman AL, Gordon SC. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. American Journal of Gastroenterology 1998;93(12):2452-6.

63. Chu CW, Hwang SJ, Luo JC, et al. Clinical, virologic, and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C. J Clin Gastroenterol 2001;32(3):240-4.

64. Shima T, Tada H, Morimoto M, et al. Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. Journal of Gastroenterology and Hepatology 2000;15(3):294-9.

65. Verbaan H, Bondeson L, Eriksson S. Non-invasive assessment of inflammatory activity and fibrosis (grade and stage) in chronic hepatitis C infection. Scandinavian Journal of Gastroenterology 1997;32(5):494-9.

66. Kjaergard LL, Krogsgaard K, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ 2001;323:1151-5.

67. Cummings KJ, Lee SM, West ES, et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: a meta-analysis of randomized trials. JAMA 2001;285(2):193-9.

68. Cheng SJ, Bonis PA, Lau J, et al. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. Hepatology 2001;33(1):231-40.

69. Fried MW, Shiffman ML, Reddy RK, et al. Pegylated (40 kDa) interferon alfa-2a (PEGASYS) in combination with ribavirin: efficacy and safety results from a phase III, randomized, actively-controlled multicenter study. Gastroenterology 2001;120(2 Suppl):A289.

70. Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001;33(2):433-8.

71. el-Zayadi A, Selim O, Haddad S, et al. Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients. Ital J Gastroenterol and Hepatology 1999;31(6):472-5.

72. Ferenci P, Brunner H, Nachbaur K, et al. Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology 2001;34(5):1006-11.

73. Helbling B, Stamenic I, Viani F, et al. Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. Hepatology 2002;35(2):447-54.

74. Tabon M, Laudi C, Delmastro B, et al. Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients. Journal of Hepatology 2001;35(4):517-21.

75. Caronia S, Bassendine MF, Barry R, et al. Interferon plus amantadine versus interferon alone in the treatment of naive patients with chronic hepatitis C: a UK multicentre study. Journal of Hepatology 2001;35(4):512-6.

76. Younossi ZM, Mullen KD, Zakko W, et al. A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy. Journal of Hepatology 2001;34(1):128-33.

77. Barbaro G, Di Lorenzo G, Soldini M, et al. Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Multicenter Interferon Beta Italian Group Investigators. Scandinavian Journal of Gastroenterology 1999;34(9):928-33.

78. Bresci G, Parisi G, Bertoni M, et al. High-dose interferon plus ribavirin in chronic hepatitis C not responding to recombinant alpha-interferon. Dig Liver Dis 2000;32(8):703-7.

79. Ferenci P, Stauber R, Steindl-Munda P, et al. Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: final results of a prospective randomized trial. Eur J Clin Gastroenterol Hepatol 2001a;13(6):699-705.

80. Tripi S, DiGaetano G, Soresi M, et al. Interferon-alpha alone versus interferon-alpha plus ribavirin in patients with chronic hepatitis C not responding to previous interferon-alpha treatment. Biodrugs 2000;13(4):299-304.

81. Puoti M, Cadeo G P, Putzolu V, et al. Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone. Dig Liver Dis 2001;33(2):163-72.

82. Chapman BA, Stace NH, Edgar CL, et al. Interferon-alpha2a/ribaviran versus interferon-alpha2a alone for the retreatment of hepatitis C

patients who relapse after a standard course of interferon. New Zealand Medical Journal 2001;114(1128):103-4.

83. Marco VD, Almasio P, Vaccaro A, et al. Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months. Journal of Hepatology 2000;33(3):456-62.

84. Cavalletto L, Chemello L, Donada C, et al. The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group. Journal of Hepatology 2000;33(1):128-34.

85. Enriquez J, Gallego A, Torras X, et al. Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone. Journal of Viral Hepatitis 2000;7(6):403-8.

86. Min AD, Jones JL, Esposito S, et al. Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone. American Journal of Gastroenterology 2001;96(4):1143-9.

87. Bonkovsky HL, Stefancyk D, McNeal K, et al. Comparative effects of different doses of ribavirin plus interferon-alpha 2b for therapy of chronic hepatitis C: results of a controlled, randomized trial. Digestive Diseases and Sciences 2001;46(10):2051-9.

88. Gaeta GB, Stornaiuolo G, Stanzione M, et al. Interferon-alpha plus amantadine in chronic hepatitis C resistant to interferon alone: a pilot randomized study. Journal of Viral Hepatitis 2001;8(4):284-6.

89. Teuber G, Berg T, Naumann U, et al. Randomized, placebo-controlled, double-blind trial with interferon-alpha with and without amantadine sulphate in primary interferon-alpha nonresponders with chronic hepatitis C. Journal of Viral Hepatitis 2001;8(4):276-83.

90. Brillanti S, Levantesi F, Masi L, et al. Triple antiviral therapy as a new option for patients with interferonnonresponsive chronic hepatitis C. Hepatology 2000;32(3):630-4.

91. Chemello L, Cavalletto L, Donada C, et al. Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C. Gastroenterology 1997;113(5):1654-9.

92. Gaeta GB, DiVirgilio D, Russo G, et al. Human leucocyte interferon-alpha in chronic hepatitis C resistant to recombinant or lymphoblastoid interferon-alpha: a randomized controlled trial. Journal of Viral Hepatitis 1997;4(3):209-14.

93. Heathcote EJ, Keeffe EB, Lee SS, et al. Re-treatment of chronic hepatitis C with consensus interferon . Hepatology 1998;27(4):1136-43.Erratum in: Hepatology 1998 Aug;28(2):599.

94. Kagawa T, Hosoi K, Takashimizu S, et al. Comparison of two interferon alfa treatment regimens characterized by an early virological response in patients with chronic hepatitis C. American Journal of Gastroenterology 1998;93(2):192-6.

95. Poynard T, Daurat V, Chevret S, et al. A short induction regimen of interferon-alpha is not effective for treatment of relapse in chronic hepatitis C: a randomized trial. For the multicentre GER-CYT-01 group. Journal of Viral Hepatitis 1999;6(5):381-6.

96. Shiffman ML, Hofmann CM, Contos MJ, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999;117(5):1164-72.

97. Bresci G, Parisi G, Babnti S, et al. Chronic hepatitis-C - what treatment for nonresponsers to recombinant interferon-alpha. Clin Drug Invest 1996;11(4):224-8.

98. Reddy KR, Hoofnagle JH, Tong MJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology 1999;30(3):787-93.

99. Campistol JM, Esforzado N, Martinez J, et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology, Dialysis, Transplantation 1999;14(11):2704-9.

100. Rumi MG, Santagostino E, Morfini M, et al. A multicenter controlled, randomized, open trial of interferon alpha-2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. Blood 1997;89(10):3529-33.

101. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352(9138):1426-32.

102. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New England Journal of Medicine 1998;339(21):1485-92.

103. Horiike N, Fujisawa T, Michitaka K, et al. The effectiveness of interferon therapy on occurrence of hepatocellular carcinoma in chronic hepatitis C. Oncology Reports 1998;5(5):1171-4.

104. Bernardinello E, Cavalletto L, Chemello L, et al. Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group. Hepatogastroenterologyogy 1999;46(30):3216-22.

105. Chemello L, Cavalletto L, Bernardinello E, et al. Comparison of thrice weekly vs daily human leucocyte interferon-alpha therapy for chronic hepatitis C. TVVH Study Group. Journal of Viral Hepatitis 1999;6(4):321-7.

106. Cottone M, Turri M, Caltagirone M, et al. Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein. Journal of Hepatology 1994;21:1029-34.

107. Shindo M, Hamada K, Oda Y, et al. Long-term follow-up study of sustained biochemical responders with interferon therapy. Hepatology 2001;33(5):1299-302.

108. Tanaka H, Tsukuma H, Kasahara A, et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. International Journal of Cancer 2000;87(5):741-9.

109. Yabuuchi I, Imai Y, Kawata S, et al. Long-term responders without eradication of hepatitis C virus after interferon therapy: characterization of clinical profiles and incidence of hepatocellular carcinoma. Liver 2000;20(4):290-5.

110. Inoue A, Tsukuma H, Oshima A, et al. Effectiveness of interferon therapy for reducing the incidence of hepatocellular carcinoma among patients with type C chronic hepatitis. Journal of Epidemiology 2000;10(4):234-40.

111. Nishiguchi S, Shiomi S, Nakatani S, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001;357(9251):196-7.

112. Toyoda H, Kumada T, Nakano S, et al. Effect of the dose and duration of interferon-alpha therapy on the incidence of hepatocellular carcinoma in noncirrhotic patients with a nonsustained response to interferon for chronic hepatitis C. Oncology 2001;61(2):134-42.

113. Ikeda K, Saitoh S, Kobayashi M, et al. Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study. Journal of Gastroenterology and Hepatology 2001;16(4):406-15.

114. Yatsuhashi H, Yano M. Natural history of chronic hepatitis C. Journal of Gastroenterology and Hepatology 2000;15 Suppl:E111-6.

115. Aizawa Y, Shibamoto Y, Takagi I, et al. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis. Cancer 2000;89(1):53-9.

116. Kobayashi M, Ikeda K, Akuta N, et al. Relationship between five-year histological outcome and serial changes in serum alanine aminotransferase in patients with biochemical and virological relapse after interferon treatment for chronic hepatitis C. Intervirology 2000;43(3):174-9.

117. Bruno S, Silini E, Crosignani A, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study. Hepatology 1997;25(3):754-8.

118. Benvegnu L, Pontisso P, Cavalletto D, et al. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology 1997;25(1):211-5.

119. Shibata M, Morizane T, Uchida T, et al. Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection. Lancet 1998;351(9118):1773-7.

120. Chiaramonte M, Stroffolini T, Vian A, et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999;85(10):2132-7.

121. Gentilini P, Laffi G, Lavilla G, et al. Long course and prognostic factors of virus-induced cirrhosis of the liver. American Journal of Gastroenterology 1997;92(1):66-72.

122. Ikeda K, Satoshi S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;12:47-53.

123. Takano S, Yokosuka O, Imazeki F, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995;21:650-55.

124. Persico M, Persico E, Suozzo R, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000;118(4):760-4.

125. Hayashi J, Furusyo N, Ariyama I, et al. A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia. J Infect Dis 2000;181(5):1523-7.

126. Furusyo N, Hayashi J, Kanamoto-Tanaka Y, et al. Liver damage in hemodialysis patients with hepatitis C virus viremia: a prospective 10-year study. Digestive Diseases and Sciences 2000;45(11):2221-8.

127. Kliem V, Van Den Hoff U, Brunkhorst R, et al. The long-term course of hepatitis C after kidney transplantation. Transplantation 1996;62(10):1417-21.

128. Rostaing L, Rumeau JL, Cisterne JM, et al. Liver histology in renal transplant patients after more than 10 years of hepatitis C virus infection. Transplantation Proceedings 1996;28(5):2836-7.

129. Lesens O, Deschenes M, Steben M, et al. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 1999;179:1254-8.

130. Benhamou Y, Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: Impact of protease inhibitor therapy. Hepatology 2001;34(2):283-7.

131. Harris HE, Ramsay ME, Andrews N, Eldridge KP. Clinical course of hepatitis C virus during the first decade of infection: cohort study. BMJ 2002;324:1-6.

132. Murakami C, Hino K, Korenaga M, et al. Factors predicting progression to cirrhosis and hepatocellular carcinoma in patients with transfusion-associated hepatitis C virus infection. J Clin Gastroenterol 1999;28(2):148-52.

133. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection. JAMA 2000;284(4):450-6.

134. Rodger AJ, Thomson JA, Thompson SC, et al. Assessment of long-term outcomes of hepatitis C virus infection in a cohort of patients with acute hepatitis in 1971-1975: results of a pilot study. Journal of Gastroenterology and Hepatology. 1999;14:269-73.

135. Kobayashi M, Tanaka E, Sodeyama T, et al. The natural course of chronic hepatitis-C - a comparison between patients with genotype-1 and genotype-2 hepatitis-C viruses. Hepatology 1996;23(4):695-9.

136. Matsumura H, Moriyama M, Goto I, et al. Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C - a study of 527 patients at one establishment. Journal of Viral Hepatitis 2000;7(4):268-75.

137. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23(6):1334-40.

138. Meijer K, Haagsma EB, Kok T, et al. Natural history of hepatitis C in HIV-negative patients with congenital coagulation disorders. Journal of Hepatology 1999;31(3):400-6.

139. Barrett S, Goh J, Coughlan B, et al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. Gut 2001;49(3):423-30.

140. Punyagupta S, Jidpugdeebodin S, Siwadune T. Hepatitis C infection and hepatocellular carcinoma in Thailand: a long term study of 63 HCV patients. J Arch Infect Dis and Antimicrobial Agents 1999;16(1):1-5.

141. Forns X, Ampurdanes S, Sanchez-Tapias JM, et al. Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center. Journal of Hepatology 2001;35(2):265-71.

142. Parking DM, Muir CS, Whelan SL, Gao Y-T, Ferlay J, Powell J. Cancer Incidence in Five Continents. 1994 World Health Statistics Annual (Vol 6) . Lyon: IARC Scientific Publications. 117-129: World Healt Organization. Geneva: WHO; 1995

143. Bruix J. Treatment of hepatocellular carcinoma. Hepatology 1997;25(2):259-62.

144. Villeneuve JP, Desrochers M, Infante-Rivard C, et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 1994;106(4):1000-5.

145. McMahon BJ, Alberts SR, Wainwright RB, et al. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Archives of Internal Medicine 1990;150(5):1051-4.

146. Sherman KE, Lewey SM, Goodman ZD. Talc in the liver of patients with chronic hepatitis C infection. American Journal of Gastroenterology 1995;90(12):2164-6.

147. Solmi L, Primerano AMM, Gandolfi L. Ultrasound follow-up of patients at risk for hepatocellular-carcinoma - results of a prospective study on 360 cases. American Journal of Gastroenterology 1996;91(6):1189-94.

148. Larcos G, Sorokopud H, Berry G, et al. Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis: an evaluation. AJR. American Journal of Roentgenology 1998;171(2):433-5.

149. Tong MJ, Blatt LM, Kao VW. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. Journal of Gastroenterology and Hepatology 2001;16(5):553-9.

150. Tradati F, Colombo M, Mannucci PM, et al. A prospective multicenter study of hepatocellular carcinoma in italian hemophiliacs with chronic hepatitis C. The Study Group of the Association of Italian Hemophilia Centers. Blood 1998;91(4):1173-7.

151. Raedle J, Roth WK, Oremek G, et al. Alpha-fetoprotein and p53 autoantibodies in patients

with chronic hepatitis C. Digestive Diseases and Sciences 1995;40(12):2587-94.

152. Tsai JF, Jeng JE, Chuang LY, et al. Clinical evaluation of urinary transforming growth factor-beta 1 and serum alpha-fetoprotein as tumour markers of hepatocellular carcinoma. Br J Cancer 1997;75(10):1460-6.

153. Izzo F, Cremona F, Ruffolo F, et al. Outcome of 67 patients with hepatocellular cancer detected during screening of 1125 patients with chronic hepatitis. Annals of Surgery 1998;227(4):513-8.

154. Ishii M, Gama H, Chida N, et al. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. American Journal of Gastroenterology 2000;95(4):1036-40.

155. Sassa T, Kumada T, Nakano S, et al. Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology 1999;11(12):1387-92.

156. VanRoey G, Fevery J, VanSteenbergen W. Hepatocellular carcinoma in Belgium: clinical and virological characteristics of 154 consecutive cirrhotic and non-cirrhotic patients. Eur J Clin Gastroenterol Hepatol 2000;12(1):61-6.

157. Cedrone A, Covino M, Caturelli E, et al. Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients. Hepatogastroenterologyogyogy 2000;47(36):1654-8.

158. Trevisani F, D'Intino PE, Caraceni P, et al. Etiologic factors and clinical presentation of hepatocellular carcinoma. Cancer 1995;75:2220-32.

159. Tsai J-F, Chang WY, Jeng JE, et al. Frequency of raised alpha-fetoprotein level among Chinese patients with hepatocellular carcinoma related to hepatitis B and C. Br J Cancer 1994;69(6):1157-9.

160. Sato Y, Nakata K, Kato Y, et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. New England Journal of Medicine 1993;328:1802-6.

161. Tsai JF, Jeng JE, Ho MS, et al. Clinical evaluation of serum alpha-getoprotein and circulating immune complexes as tumour markers of hepatocellular carcinoma. Br J Cancer 1995;72:442-6.

162. Nomura F, Ishijima M, Horikoshi A, et al. Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: comparison of the conventional enzyme immunoassay and two modified methods. American Journal of Gastroenterol 1996;91(7):1380-3.

163. Izzo F, Cremona F, Delrio P, et al. Soluble interleukin-2 receptor levels in hepatocellular cancer: a more sensitive marker than alfa fetoprotein. Annals of Surgical Oncology 1999;6(2):178-85.

164. Kakumu S, Okumura A, Ishikawa T, et al. Serum levels of Il-10, Il-15 and soluble tumour necrosis factor-alpha (TNF-alpha) receptors in type C chronic liver disease. Clinical and Experimental Immunology 1997;109(3):458-63.

165. Nagai T, Murota M, Nishioka M, et al. Elevation of cytokeratin 19 fragment in serum in patients with hepatoma: its clinical significance. European Journal of Gastroenterol and Hepatology 2001;13(2):157-61.

166. Tsuzurahara S, Sata M, Iwamoto O, et al. Detection of MAGE-4 protein in the sera of patients with hepatitis-C virus-associated hepatocellular carcinoma and liver cirrhosis. Japanese Journal of Cancer Research 1997;88(9):915-8.

167. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and

its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998;27(5):1394-402.

168. Colombo M, Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. New England Journal of Medicine 1991;325:675.

169. Walsh KM, Timms P, Campbell S, et al. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Digestive Diseases and Sciences 1999a;44(3):624-30.

170. Davidoff F, DeAngelis CD, Drazen JM, et al. Sponsorship, authorship, and accountability. New England Journal of Medicine 2001;345(11):825-6.